Thromboelastogram reduces blood use by inspecting coagulation in heart surgery

Influence of Lower Extremity Deep Venous Thrombosis in Cerebral Infarction on Coagulation Index and Thromboelastogram and Its Risk Factors

Cerebral infarction is a serious brain injury disease, which is mainly caused by the blockage of blood circulation in patients’ brains; thus, the patient’s brain appears ischemia and hypoxia state, and large-scale nerve cell death occurs immediately. The aim of this study was to explore the influence of lower extremity deep venous thrombosis (LEDVT) on coagulation indexes and thromboelastogram (TEG) after cerebral infarction. Altogether, 67 patients with cerebral infarction complicated with LEDVT in our hospital from April 2017 to August 2019 were collected as the observation group (OG) and 58 patients with cerebral infarction without lower extremity deep venous thrombosis as the control group (CG). The R, K, angle, and MA values in PT, APTT, TT, FIB, and TEG indexes were compared between the two groups. The ROC curve was applied to analyze the diagnostic value of R value, K value, angle value, and MA value in the occurrence of LEDVT in patients with cerebral infarction. Logistic regression analysis was applied to analyze the independent risk factors of lower extremity deep venous thrombosis in cerebral infarction. PT, APTT, and TT in the OG were evidently lower than those in the CG, while FIB in the OG was evidently higher than that in the CG, R value and K value of the OG were evidently lower than those of the CG, and angle and MA values were higher than those in the CG. The AUC of R value, K value, angle value, and MA value of the ROC curve of LEDVT in patients with cerebral infarction was 0.735, 0.713, 0.790, and 0.819. Multivariate analysis showed that high FIB, angle, and MA were risk factors, while R and K values were protective factors. PT, APTT, and TT are lower and FIB is higher in patients with cerebral infarction with LEDVT. TEG has a certain diagnostic value. FIB value, angle value, and MA value are independent risk factors of LEDVT in patients with cerebral infarction, while R value and K value are protective factors.

Thromboelastography and rotational thromboelastometry in bleeding patients with coagulopathy: Practice management guideline from the Eastern Association for the Surgery of Trauma

BACKGROUND

Assessment of the immediate need for specific blood product transfusions in acutely bleeding patients is challenging. Clinical assessment and commonly used coagulation tests are inaccurate and time-consuming. The goal of this practice management guideline was to evaluate the role of the viscoelasticity tests, which are thromboelastography (TEG) and rotational thromboelastometry (ROTEM), in the management of acutely bleeding trauma, surgical, and critically ill patients.

METHODS

Systematic review and meta-analyses of manuscripts comparing TEG/ROTEM with non-TEG/ROTEM-guided blood products transfusions strategies were performed. The Grading of Recommendations Assessment, Development and Evaluation methodology was applied to assess the level of evidence and create recommendations for TEG/ROTEM-guided blood product transfusions in adult trauma, surgical, and critically ill patients.

RESULTS

Using TEG/ROTEM-guided blood transfusions in acutely bleeding trauma, surgical, and critically ill patients was associated with a tendency to fewer blood product transfusions in all populations. Thromboelastography/ROTEM-guided transfusions were associated with a reduced number of additional invasive hemostatic interventions (angioembolic, endoscopic, or surgical) in surgical patients. Thromboelastography/ROTEM-guided transfusions were associated with a reduction in mortality in trauma patients.

CONCLUSION

In patients with ongoing hemorrhage and concern for coagulopathy, we conditionally recommend using TEG/ROTEM-guided transfusions, compared with traditional coagulation parameters, to guide blood component transfusions in each of the following three groups: adult trauma patients, adult surgical patients, and adult patients with critical illness.

LEVEL OF EVIDENCE

Systematic Review/Meta-Analysis, level III.

Analysis of thrombelastogram-guided medication in patients with coronary heart disease after percutaneous coronary intervention

Effects of thrombelastogram-guided (TEG-guided) clopidogrel and aspirin on major adverse cardiovascular events (MACE) after percutaneous coronary intervention (PCI) were investigated. A retrospective analysis was performed on 203 patients undergoing PCI interventional therapy in the Cardiovascular Medicine of Weihai Central Hospital from February 2015 to September 2016. The patients were treated with clopidogrel and aspirin for anti-thrombus therapy. Among them, 104 patients who had TEG detection of anticoagulant effects for guiding medication were the experimental group, and 99 patients without TEG detection for guiding medication the control group. The coagulation function and the platelet inhibition rate of patients after medication were evaluated and compared between the two groups. The incidence of MACE and bleeding events of patients was counted during three months of follow-up. Patients in the experimental group had higher R (coagulation reaction time) value and K (blood clot formation time) value than those in the control group after treatment (P<0.05), and lower MA (maximum amplitude) value than those in the control group (P<0.05). Patients in the experimental group had higher postoperative platelet inhibition rate than those in the control group (P<0.05). Patients in the experimental group had lower incidence of MACE and bleeding events than those in the control group (P<0.05). Coronary heart disease (CHD) patients after PCI with the TEG-guided dose adjustment of clopidogrel have more satisfactory treatment effects than patients without the TEG guidance. TEG makes the treatment of patients more targeted and is worthy of promotion.